🎉 Binette is now published in JOSS ! joss.theoj.org/papers/10.2110… Binette is a bin refinement tool that creates high-quality MAGs from multiple binning tools. Inspired by MetaWRAP bin refinement but faster and more accurate 🎯 Check out its Github github.com/genotoul-bioin…

📅- [#Event] – Meet Sian Crouzet, Chief Financial Officer at MaaT Pharma, and Guilhaume Debroas, Head of Investor Relations at MaaT Pharma, during the Investor Access Forum, on October 15 & 16, 2024, at Maison de la Chimie, Paris. Looking forward to sharing our development with you!

Big news from us, MaaT Pharma! Proud to be part of this team and one step closer to bringing #MaaT013 to patients! @MaaTPharma #GvHD #Oncology #ClinicalTrials #Teamwork #Microbiome #Innovation

Attention, grosses news! Proud to be part of this team and one step closer to bringing #MaaT013 to patients! @MaaTPharma #GvHD #Oncology #ClinicalTrials #Teamwork #Microbiome #Innovation

📢[#SEHH2024] - We are proud to announce that Dr. Jaime Sanz Caballer will present promising data from our Early Access program where 140 patients were treated with acute Graft-versus-Host Disease (#aGvHD) with MaaT013, our lead asset currently in a fully recruited Phase 3 trial.

If this is not a sign of the microbiome research impact in cancer immunotherapy! Excellent news for the domain! #microbiome #immunotherapy #SITC24

We are happy to announce that the MaAslin3 manuscript is now available on bioRxiv! Check it out and feel free to post feedback on our forums! biorxiv.org/content/10.110…

Birds flying high, you know how I feel Sun in the sky, you know how I feel Breeze driftin' on by, you know how I feel ;-)

📅 [#Event] – We are thrilled to share that Gianfranco Pittari, MD PhD, Chief Medical Officer at MaaT Pharma, will present the Positive Phase 3 data for our lead asset MaaT013 in treating aGvHD at the Microbiome Times Partnering Forum, organized by The The Microbiome Times and in

The best opening slide doesn't exi...

📄[Press release] – MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 for the treatment of acute Graft-versus-Host Disease🩸 Read the press release: maatpharma.com/march-11-2025-… #BloodCancer #Cancer #EMA #aGvHD

📄[Communiqué de presse] – MaaT Pharma reçoit un avis positif du Comité Pédiatrique de l'EMA pour le plan d'investigation pédiatrique de MaaT013 dans le traitement de la maladie aiguë du greffon contre l’hôte🩸 Voir le communiqué de presse : maatpharma.com/fr/11-mars-202… #EMA #MaaT013

💬 “These data clearly confirm the efficacy of MaaT013 in aGvHD,” said Prof. Mohty Mohamad Mohty at #EHA2025 during oral presentation. With a favorable safety profile, Xervyteg® (MaaT013) our full-ecosystem microbiotherapy is showing real promise in a high unmet need and we are

EN- 📅 [#Event] – Guilhaume Debroas, Ph.D, Head of Investor Relations at MaaT Pharma, will participate in the MID & SMALL CAPS 2025 Conference by Portzamparc, taking place on June 18-19 in Paris. 📍 Join us at the Étoile Business Center (21-25 Rue Balzac, 75008 Paris), for

🦠 [#WMD2025] - How Microbiome Research Is Transforming Medicine? To mark World Microbiome Day 2025, we spoke with Dr. Joël Doré, Research Director at INRAE, Scientific advisor, co-founder of MaaT Pharma, and one of the world’s leading microbiome experts. Dr. Doré describes

.MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe bit.ly/3ZXfPMU

Did you see that? It’s quite big! 👇 So happy to see our first product finding a way to reach more and more patients. What an achievement!

📄 [Press release] – MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (European Investment Bank ) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology This structured debt financing will support the advancement of our late-stage clinical assets, including: -

[Health for Life Capital portfolio] 🙌MaaT Pharma lands €37.5M from European Investment Bank to accelerate #cancer therapy development. Xervyteg® under EMA review, MaaT033 in Phase 2b trials. Full press release 👉 ow.ly/cmL350WvSlw #Microbiome 🦠

To all of the folk saying we need deep learning for RNA-seq prediction...